Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3.
| CAS Number | 1969309-56-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[4] No authors listed. Cancer Discov. Zenocutuzumab Shines in PDAC
[5] Daniel Eiger, et al. Cancers (Basel). The Exciting New Field of HER2-Low Breast Cancer Treatment
| Related EGFR/HER2 Products |
|---|
| Zongertinib
Zongertinib (BI 1810631) is a human HER2-selective tyrosine kinase inhibitor that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertion mutations, whilst sparing EGFR signaling. Zongertinib has antitumor activity. |
| Inetetamab
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab shows antitumor activities when used alone or together with tyrosine kinase inhibitors. |
| BBT-207
BBT-207 is a reversible, mutant-specific EGFR inhibitor with antitumor activity. |
| VRN-11
VRN-11 is an EGFR C797S inhibitor. |
| TRX-221
TRX-221 is an EGFR C797S inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
